KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
KalVista Pharmaceuticals, Inc. KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from the phase 2 trial evaluating the …